| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d7bee24c10d58e60f4abd6a5ea5b0091
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_91e2cb26955bbd751109d3c35b48a395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e13e4c13fe64996895413453879610c3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a583ac8ac8f8c952847026833ecda0ac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6c1ed9172be30413aa370d8589890799 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3515
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-321
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-111
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1135 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
| filingDate |
2008-02-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93dbab2be524740fa845df8e1486a0d0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_45f88e6c07c362faf66ff706dbc47764
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c74a5b34c8d64da50e938c245854ddc5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_07971722a39ebdc3c84ae2498442c432 |
| publicationDate |
2009-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2008109470-A9 |
| titleOfInvention |
Nucleic acid compounds for inhibiting ptpn1 gene expression and uses thereof |
| abstract |
The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing PTPNl gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a PTPNl mRNA. In addition, the meroduplex may have at least one uridine is a 5-methyluridine, a nucleoside is a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a PTPNl gene in a cell or in a subject to treat a PTPNl -related disease. |
| priorityDate |
2007-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |